AZA/Tacrolimus is associated with similar outcomes as mmf/tacrolimus among renal transplant recipients

J. D. Schold, B. Kaplan

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

There have been several retrospective studies indicating benefits associated with mycophenalate mofetil (MMF) compared to azathioprine (AZA) for renal transplant recipients. However, these analyses evaluated outcomes prior to changes in utilization patterns of concomitant immunosuppression. Recent prospective trials have indicated similar outcomes among patients treated with MMF and AZA. The aim of this study was to evaluate outcomes in a broad group of patients in the more recent era. We evaluated adult solitary renal transplant recipients from 1998 to 2006 with the national SRTR database. Primary outcomes were time to patient death and graft loss, complications and renal function. Models were adjusted for potential confounding factors, propensity scores and stratified between higher/lower risk transplants and concomitant immunosuppression. Adjusted models indicated a modest risk among AZA patients for graft loss (AHR = 1.14, 95% CI 1.07-1.20); however, this was not apparent among AZA patients also treated with tacrolimus (AHR = 0.97, 95% CI 0.85-1.11]. One-year acute rejection rates were reduced for patients on MMF versus AZA (10 vs. 13%, p <0.01); there were no statistically significant differences of malignancies, renal function or BK virus at 1 year. The primary findings suggest the association of MMF with improved outcomes may not be apparent in patients also receiving tacrolimus.

Original languageEnglish (US)
Pages (from-to)2067-2074
Number of pages8
JournalAmerican Journal of Transplantation
Volume9
Issue number9
DOIs
StatePublished - Sep 2009
Externally publishedYes

Fingerprint

Azathioprine
Tacrolimus
Kidney
Transplants
Immunosuppression
BK Virus
Propensity Score
Transplant Recipients
Retrospective Studies
Databases
Neoplasms

Keywords

  • Azathioprine
  • Cyclosporine
  • Graft survival
  • Immunosuppression
  • Mycophenolate mofetil
  • Tacrolimus

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

AZA/Tacrolimus is associated with similar outcomes as mmf/tacrolimus among renal transplant recipients. / Schold, J. D.; Kaplan, B.

In: American Journal of Transplantation, Vol. 9, No. 9, 09.2009, p. 2067-2074.

Research output: Contribution to journalArticle

@article{a5c82aade1354e55aaf07a6b7945cc04,
title = "AZA/Tacrolimus is associated with similar outcomes as mmf/tacrolimus among renal transplant recipients",
abstract = "There have been several retrospective studies indicating benefits associated with mycophenalate mofetil (MMF) compared to azathioprine (AZA) for renal transplant recipients. However, these analyses evaluated outcomes prior to changes in utilization patterns of concomitant immunosuppression. Recent prospective trials have indicated similar outcomes among patients treated with MMF and AZA. The aim of this study was to evaluate outcomes in a broad group of patients in the more recent era. We evaluated adult solitary renal transplant recipients from 1998 to 2006 with the national SRTR database. Primary outcomes were time to patient death and graft loss, complications and renal function. Models were adjusted for potential confounding factors, propensity scores and stratified between higher/lower risk transplants and concomitant immunosuppression. Adjusted models indicated a modest risk among AZA patients for graft loss (AHR = 1.14, 95{\%} CI 1.07-1.20); however, this was not apparent among AZA patients also treated with tacrolimus (AHR = 0.97, 95{\%} CI 0.85-1.11]. One-year acute rejection rates were reduced for patients on MMF versus AZA (10 vs. 13{\%}, p <0.01); there were no statistically significant differences of malignancies, renal function or BK virus at 1 year. The primary findings suggest the association of MMF with improved outcomes may not be apparent in patients also receiving tacrolimus.",
keywords = "Azathioprine, Cyclosporine, Graft survival, Immunosuppression, Mycophenolate mofetil, Tacrolimus",
author = "Schold, {J. D.} and B. Kaplan",
year = "2009",
month = "9",
doi = "10.1111/j.1600-6143.2009.02756.x",
language = "English (US)",
volume = "9",
pages = "2067--2074",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - AZA/Tacrolimus is associated with similar outcomes as mmf/tacrolimus among renal transplant recipients

AU - Schold, J. D.

AU - Kaplan, B.

PY - 2009/9

Y1 - 2009/9

N2 - There have been several retrospective studies indicating benefits associated with mycophenalate mofetil (MMF) compared to azathioprine (AZA) for renal transplant recipients. However, these analyses evaluated outcomes prior to changes in utilization patterns of concomitant immunosuppression. Recent prospective trials have indicated similar outcomes among patients treated with MMF and AZA. The aim of this study was to evaluate outcomes in a broad group of patients in the more recent era. We evaluated adult solitary renal transplant recipients from 1998 to 2006 with the national SRTR database. Primary outcomes were time to patient death and graft loss, complications and renal function. Models were adjusted for potential confounding factors, propensity scores and stratified between higher/lower risk transplants and concomitant immunosuppression. Adjusted models indicated a modest risk among AZA patients for graft loss (AHR = 1.14, 95% CI 1.07-1.20); however, this was not apparent among AZA patients also treated with tacrolimus (AHR = 0.97, 95% CI 0.85-1.11]. One-year acute rejection rates were reduced for patients on MMF versus AZA (10 vs. 13%, p <0.01); there were no statistically significant differences of malignancies, renal function or BK virus at 1 year. The primary findings suggest the association of MMF with improved outcomes may not be apparent in patients also receiving tacrolimus.

AB - There have been several retrospective studies indicating benefits associated with mycophenalate mofetil (MMF) compared to azathioprine (AZA) for renal transplant recipients. However, these analyses evaluated outcomes prior to changes in utilization patterns of concomitant immunosuppression. Recent prospective trials have indicated similar outcomes among patients treated with MMF and AZA. The aim of this study was to evaluate outcomes in a broad group of patients in the more recent era. We evaluated adult solitary renal transplant recipients from 1998 to 2006 with the national SRTR database. Primary outcomes were time to patient death and graft loss, complications and renal function. Models were adjusted for potential confounding factors, propensity scores and stratified between higher/lower risk transplants and concomitant immunosuppression. Adjusted models indicated a modest risk among AZA patients for graft loss (AHR = 1.14, 95% CI 1.07-1.20); however, this was not apparent among AZA patients also treated with tacrolimus (AHR = 0.97, 95% CI 0.85-1.11]. One-year acute rejection rates were reduced for patients on MMF versus AZA (10 vs. 13%, p <0.01); there were no statistically significant differences of malignancies, renal function or BK virus at 1 year. The primary findings suggest the association of MMF with improved outcomes may not be apparent in patients also receiving tacrolimus.

KW - Azathioprine

KW - Cyclosporine

KW - Graft survival

KW - Immunosuppression

KW - Mycophenolate mofetil

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=69149099929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69149099929&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2009.02756.x

DO - 10.1111/j.1600-6143.2009.02756.x

M3 - Article

C2 - 19681827

AN - SCOPUS:69149099929

VL - 9

SP - 2067

EP - 2074

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 9

ER -